Immunotherapy combined with antiangiogenic agents in patients with advanced malignant pleural mesothelioma: A case report  

作　　者：Tian-Tian Xuan Guang-Yi Li Si-Bo Meng Zhan-Mei Wang Lin-Li Qu 

机构地区：[1]Department of Medical Oncology,Qilu Hospital(Qingdao),Cheeloo College of Medicine,Shandong University,Qingdao 266035,Shandong Province,China [2]Department of Respiratory,Qilu Hospital(Qingdao),Cheeloo College of Medicine,Shandong University,Qingdao 266035,Shandong Province,China

出　　处：《World Journal of Clinical Cases》2022年第23期8284-8290,共7页世界临床病例杂志

摘　　要：BACKGROUND Malignant pleural mesothelioma has limited therapeutic options and a poor outcome. Antiangiogenic agents might increase the efficacy of immunotherapy as second-line treatment of advanced-stage malignancies.CASE SUMMARY A patient with stage ⅢB pleural mesothelioma received second-line treatment with a combination of pembrolizumab, bevacizumab and chemotherapy following standard chemotherapy under the guidance of second-generation sequencing. He achieved a partial response after four cycles of treatment with progression-free survival of 5 mo. Pembrolizumab was suspended due to grade 2 immunerelated pneumonia, which was resolved by oral glucocorticoids.However, disease progression was observed after immunotherapy rechallenge and anlotinib therapy. The patient had disease progression, multiorgan dysfuntion and died suddenly in October 2019.CONCLUSION The combination of immune checkpoint inhibitor, anti-angiogenic agents and chemotherapy showed effective response for advanced pleural mesothelioma, but with adverse reactions.

关 键 词：Pleural mesothelioma Immune checkpoint inhibitor Next-generation Sequencing Immunerelated pneumonia Immunotherapy rechallenge Case report 

分 类 号：R734.3[医药卫生—肿瘤]